Anticipating metastasis through electrochemical immunosensing of tumor hypoxia biomarkers
- 26 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Analytical and Bioanalytical Chemistry
- Vol. 414 (1), 399-412
- https://doi.org/10.1007/s00216-021-03240-8
Abstract
Metastasis is responsible for about 90% of cancer-associated deaths. In the context of solid tumors, the low oxygen concentration in the tumor microenvironment (hypoxia) is one of the key factors contributing to metastasis. Tumor cells adapt to these conditions by overexpressing certain proteins such as programmed death ligand 1 (PD-L1) and hypoxia-inducible factor 1 alpha (HIF-1α). However, the determination of these tumor hypoxia markers that can be used to follow-up tumor progression and improve the efficiency of therapies has been scarcely addressed using electrochemical biosensors. In this work, we report the first electrochemical bioplatform for the determination of PD-L1 as well as the first one allowing its simultaneous determination with HIF-1α. The target proteins were captured and enzymatically labeled on magnetic microbeads and amperometric detection was undertaken on the surface of screen-printed dual carbon electrodes using the hydrogen peroxide/peroxidase/hydroquinone system. Sandwich immunoassays were implemented for both the HIF-1α and PD-L1 sensors and the analytical characteristics were evaluated providing LOD values of 86 and 279 pg mL−1 for the amperometric determination of PD-L1 and HIF-1α standards, respectively. The developed electrochemical immunoplatforms are competitive versus the only electrochemical immunosensor reported for the determination of HIF-1α and the “gold standard” ELISA methodology for the single determination of both proteins in terms of assay time, compatibility with the simultaneous determination of both proteins making their use suitable for untrained users at the point of attention. The dual amperometric immunosensor was applied to the simultaneous determination of HIF-1α and PD-L1 in cancer cell lysates. The analyses lasted only 2 h and just 0.5 μg of the sample was required. Graphical abstractKeywords
Funding Information
- Spanish Ministerio de Ciencia e Innovación (PID2019-103899RB-I00)
- AES-ISCIII (PI20CIII/00019)
- Comunidad de Madrid (S2018/NMT-4349)
- Spanish Ministerio de Ciencia, Innovación y Universidades (RTI2018-096135-B-I00)
This publication has 63 references indexed in Scilit:
- Electrochemical magnetic microbeads-based biosensor for point-of-care serodiagnosis of infectious diseasesBiosensors and Bioelectronics, 2016
- Non–Small Cell Lung Cancer, PD-L1, and the PathologistArchives of Pathology & Laboratory Medicine, 2016
- Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patientsVirchows Archiv, 2016
- Associations among pretreatment tumor necrosis and the expression of HIF-1α and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereofOral Oncology, 2015
- Computational tools for fitting the Hill equation to dose–response curvesJournal of Pharmacological and Toxicological Methods, 2015
- PD-L1 and MHC-I expression in 19 human tumor cell lines and modulation by interferon-gamma treatmentJournal for ImmunoTherapy of Cancer, 2014
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activationThe Journal of Experimental Medicine, 2014
- A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer CellsCancer Research, 2014
- Cardiac Troponin AssaysCirculation, 2007
- Development of an Amperometric Immunosensor for the Quantification of Staphylococcus aureus Using Self‐Assembled Monolayer‐Modified Electrodes as Immobilization PlatformsElectroanalysis, 2007